trending Market Intelligence /marketintelligence/en/news-insights/trending/rl9ffgxvzwdbhf_elmmyeq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it failed to comply with Nasdaq's $1 minimum bid price per common share.

The company has 180 calendar days, or until Feb. 25, 2019, to regain compliance.

The current notice has no immediate effect on the company's listing.

New Jersey-based ContraVir Pharmaceuticals develops antiviral drugs with a focus on hepatitis B.